Insilico Medicine, a biotechnology company developing end-to-end drug discovery pipelines utilizing the next-generation artificial intelligence, to present new results of its generative biology pipeline resulting in novel targets in liver disease.
The company will showcase the results of the first experimental validation of its generative biology target ID system at CTIC on the 12th of January, 2020 and at Biotech Showcase, 13th of January, 2020.
For the first time, we will present the results of our generative biology pipeline resulting in novel targets for liver disease during the JP Morgan. This is a major milestone for us, and we are happy to continue making history in AI-powered biomedicine."
Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine
You can also meet Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine at FierceBiotech Executive Breakfast on the 14th of January, 2020.
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine